Because undesirable pharmacokinetics and toxicity are significant reasons for the failure of
drug development in the costly late stage, it has been widely recognized that drug ADMET …

Abstract Background Cytochrome P450s (CYPs) are a class of hemoproteins involved in
drug metabolism. It has been reported that body composition, proportion of dietary …

OBJECTIVES: Proton pump inhibitors (PPIs) are often used in pediatrics to treat common
gastrointestinal disorders, and there are growing concerns for infectious adverse events …

Introduction Erosive esophagitis (EE) occurs when refluxate from the stomach causes T-
lymphocyte infiltration of the esophageal mucosa, resulting in mucosal breaks. Currently …

Medications used for supportive care or prophylaxis constitute a significant portion of drug
utilization in the intensive care unit. Evidence-based guidelines are available for many …

Background: Ruminant species are at risk of developing abomasal ulceration, but there is a
lack of pharmacokinetic data for anti-ulcer therapies, such as the proton pump inhibitor …

Despite a growing interest in, and commitment to, implementing pediatric clinical trials,
approximately one in every five trials in children fails because of inappropriate study design …

Background Obesity is related to many pathophysiological changes that may result in
altered drug disposition. Omeprazole is the most common option utilized for acid-related …

Obesity rates continue to rise in children, and little guidance exists regarding the need for
adjustment away from total body weight-based doses for those prescribing drugs to this …

Pharmacogenetics is a key component of precision medicine. Genetic variation in drug
metabolism enzymes can lead to variable exposure to drugs and metabolites, potentially …